Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis

Application of the anticancer drug doxorubicin (DOX) is restricted due to its adverse, cardiotoxic side effects, which ultimately result in heart failure. Moreover, there are a limited number of chemical agents for the clinical prevention of DOX-induced cardiotoxicity. Based on the theories of tradi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xutao, Song, Yunjia, Xie, Ying, Han, Jieru, Chen, Fei, Sun, Yang, Sui, Bowen, Jiang, Deyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310442/
https://www.ncbi.nlm.nih.gov/pubmed/34326887
http://dx.doi.org/10.1155/2021/6659676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310442/
https://www.ncbi.nlm.nih.gov/pubmed/34326887
http://dx.doi.org/10.1155/2021/6659676

Ejemplares similares